Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fourteen analysts that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 […]
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fourteen analysts that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 […]
